Abstracts tagged "Pathology Bone Joint"

Abstract Number: 0852 • ACR Convergence 2024
3-dimensional Shape Changes of the Knee over 4 Years Are Linear and Progressive but Much More Rapid in Osteoarthritic Joints: Data from the Osteoarthritis Initiative
Alan Brett¹, Philip G Conaghan² and Michael Bowes³, ¹Imorphics, Austin, TX, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³Imorphics, Manchester, United Kingdom
Background/Purpose: The specific bony changes of osteophyte growth and “bone attrition” (broadening and flattening of the femoral condyles) associated with OA have been recognized in…
Abstract Number: 0418 • ACR Convergence 2023
Synovial Fluid Cell Counts Associated with Joint Histopathology in Rheumatoid Arthritis
Edoardo Spolaore¹, Edward DiCarlo², Daniel Ramirez², Melanie Smith², Amit Lakhanpal², Bella Mehta³, Laura Donlin², Susan Goodman² and Dana Orange⁴, ¹HSS, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴The Rockefeller University, New York, NY
Background/Purpose: While analysis of synovial fluid white blood cell counts (WBCs) is performed in clinical practice for diagnosing septic arthritis and differentiating noninflammatory from inflammatory…
Abstract Number: 0503 • ACR Convergence 2023
Spinal Inflammation a Dominant Pathology in Psoriatic Arthritis: Characterization and Quantification by In-Vivo 18F-FDG Total-Body PET/CT Imaging
Siba Raychaudhuri¹, Yasser Abdelhafez², Dario Mazza², Smriti K Raychaudhuri³ and Abhijit Chaudhari⁴, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ²University of California Davis, Sacramento, CA, ³VA Sacramento Medical Center, Mather, CA, ⁴UC Davis School of Medicine, Sacramento, CA
Background/Purpose: Right and Moll recognized the presence of spinal inflammation/axial disease in psoriatic arthritis (PsA) in their seminal work in 1973. The prevalence of axial…
Abstract Number: 0862 • ACR Convergence 2023
Role of CRTAC1 as a Biomarker of Osteoarthritis
Aneta Pekacova¹, Jiri Baloun², Adela Navratilova³, Lucia Ondrejcakova⁴, Jana Zborovjanova⁴, Petr Fulin⁵, Rastislav Ballay⁶, Michal Tomcik⁷ and Ladislav Senolt⁸, ¹First faculty of medicine, Charles University, Prague, Czech Republic, ²Institute of Rheumatology, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Hlavní město Praha, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵First Department of Orthopaedics, First Faculty of Medicine of Charles University and Motol University Hospital, Prague, Czech Republic, ⁶First Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, ⁷Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁸Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic
Background/Purpose: Cartilage acidic protein-1 (CRTAC1) has been recently considered a promising biomarker of osteoarthritis (OA) progression (1,2). The aim of this study is to compare…
Abstract Number: 1630 • ACR Convergence 2023
Patient-Reported Fatigue Associated with Joint Histopathology in Rheumatoid Arthritis
Diyu Fisher¹, Dana Orange², Melanie Smith³, Bella Mehta⁴, Edoardo Spolaore⁵, Edward DiCarlo³, Dongmei Sun³, Laura Donlin³ and Susan Goodman³, ¹Stony Brook Medicine, Port Jefferson Station, NY, ²The Rockefeller University, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵HSS, New York, NY
Background/Purpose: Fatigue or tiredness is an important symptom for patients with rheumatoid arthritis (RA), yet the factors associated with fatigue are poorly understood and may…
Abstract Number: 1919 • ACR Convergence 2023
Arthroplasty Outcomes in Immune Checkpoint Inhibitor-Treated Patients: A Single Center Series
Yasmine Elfarra¹, Edward DiCarlo², Jonathan Vigdorchik², Carlos Aude³, Nilasha Ghosh³, Anne Bass³ and Karmela Kim Chan², ¹Weill Cornell, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) have changed the landscape of cancer treatment dramatically, but because of their mechanism of action they are also known to…
Abstract Number: 2066 • ACR Convergence 2023
Ultrasound Guided Synovial Biopsy Course: Achievement of Learner Self Efficacy
Diane Horowitz¹, Darren Tabechian², Ami Ben-Artzi³, Karina Torralba⁴ and Arthur Mandelin⁵, ¹Northwell Health, Great Neck, NY, ²University of Rochester Medical Center, Rochester, NY, ³Ami Ben Artzi, MD, San Diego, CA, ⁴Loma Linda University, Loma Linda, CA, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: Ultrasound guided synovial biopsy (UGSB) is a minimally invasive, safe and effective tool to obtain synovium for clinical and research purposes. Described in Europe…
Abstract Number: 0726 • ACR Convergence 2021
Joint Safety of Tanezumab versus NSAIDs; A Combined Assessment of Benefit and Harm
Robert Fountaine¹, Robert Dworkin², Anne Hickman¹, Glenn Pixton³, Ed Whalen⁴, Christine West¹ and Kenneth Verburg¹, ¹Pfizer Inc., Groton, CT, ²University of Rochester, Rochester, NY, ³Pfizer Inc., Morrisville, NC, ⁴Pfizer Inc., New York, NY
Background/Purpose: Tanezumab, a monoclonal antibody against nerve growth factor, is in development for the relief of signs and symptoms of moderate to severe osteoarthritis (OA)…
Abstract Number: 1890 • ACR Convergence 2021
Cellular Origin and Functions of Osteoclasts in Inflammatory Arthritis
Hannah Nelson¹, Ellen Gravallese², Julia Charles¹ and Christian Jacome-Galarza¹, ¹Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: Inflammatory arthritis (IA) is an autoimmune disease targeting multiple joints and characterized by joint destruction caused by osteoclasts (OC), leading to physical disability. However,…
Abstract Number: 1897 • ACR Convergence 2021
A Randomized Double-Blind Controlled Trial of Intensive Serum Urate Lowering with Oral Urate-Lowering Therapy for Erosive Gout
Nicola Dalbeth¹, Anthony Doyle¹, Karen Billington¹, Gregory Gamble¹, Paul Tan¹, Kieran Latto¹, Trish Parshu Ram¹, Ravi Narang¹, Rachel Murdoch¹, David Bursill¹, Borislav Mihov¹, Lisa Stamp² and Anne Horne¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: Bone erosion is a common consequence of tophaceous gout, and leads to joint deformity and disability. In small case series, intensive urate-lowering with intravenous…
Abstract Number: 1854 • ACR Convergence 2020
NGF/TrkA System Regulates Pain and the Pannus Formation: Targeting NGF-TrkA in Psoriatic Arthritis
Siba Raychaudhuri¹ and Smriti Raychaudhuri², ¹UC Davis, School of Medicine, Davis, CA, ²VA Sacramento Medical Center, Davis, CA
Background/Purpose: Function of Nerve Growth Factor (NGF) in the nervous system and its regulatory role in pain is well defined. We have shown earlier that…
Abstract Number: 0085 • ACR Convergence 2020
Classifications of Inflammatory Myopathies: Differentially Expressed Membrane-Bound Complement Regulators Allow Specific Patterns of Membrane Attack Complex Deposition
Fadi Charouf¹, Netanel Karbian¹, Itamar Altman¹, Yakov Fellig¹ and Dror Mevorach¹, ¹Hadassah-University Hospital, Jerusalem, Yerushalayim, Israel
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of heterogeneous disorders that typically present with proximal muscle weakness. According to the classification criteria, IMs are…
Abstract Number: 0793 • ACR Convergence 2020
Topological Laser Capture Microscopy (LCM)-RNAseq to Map the Rheumatoid Arthritis (RA) Synovial Transcriptome
Benjamin Van Espen¹, Andrew Wilson¹, Gregory Seumois², Narayanan Perumal³, Robert Benschop⁴, Gary Firestein⁵, Nunzio Bottini⁵ and Stephanie Stanford¹, ¹University of California, San Diego, La Jolla, ²La Jolla Institute for Immunology, La Jolla, ³Eli Lilly, Indianapolis, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵University of California, San Diego, La Jolla, CA
Background/Purpose: Understanding pathogenic processes in the diseased tissue in rheumatoid arthritis (RA) is a critical step to defining disease pathogenesis and identifying novel therapeutic targets.…
Abstract Number: 0796 • ACR Convergence 2020
Development of a Tool to Assess Synovial Tissue Infiltrates and Derive Histological Pathotype in Inflammatory Arthritis: Relationship to Clinical and Ultrasound Variables
Hayley Carr¹, Ilfita Sahbudin¹, Mark Maybury¹, Bernard Dyke², Jason Turner³, Nicola Gullick⁴, Karim Raza⁵, Dagmar Scheel-Toellner¹ and Andrew Filer¹, ¹Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ²Institute of Inflammation and Ageing, University of Birmingham, Birmingham, England, United Kingdom, ³Rheumatology Research Group, Institute for Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Queen Elizabeth Hospital, Birmingham, United Kingdom, ⁴University Hospitals Coventry & Warwickshire, Coventry, United Kingdom, ⁵Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom
Background/Purpose: Evidence suggests that histological pathotypes are linked to pathogenic mechanisms in inflammatory arthritis and may be useful as biomarkers of outcome. The frequently used…
Abstract Number: 0875 • ACR Convergence 2020
Secukinumab Provides Sustained Improvements in Subgroup Analyses of Joint Tenderness and Swelling in Patients with Psoriatic Arthritis: 5‑Year Results from the Phase 3 FUTURE 2 Study
Iain McInnes¹, Hector Chinoy², Darren Asquith³, Abigail White³ and Corine Gaillez⁴, ¹Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²The University of Manchester, Manchester, United Kingdom, ³Novartis Pharmaceuticals UK Ltd., London, United Kingdom, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal antibody that neutralizes interleukin‑17A, has shown long-term efficacy and tolerability in patients with psoriatic arthritis (PsA) in FUTURE 2.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].